| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma (NCT01478581) | Pharmacyclics LLC. | 2012-03-01 |
| Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma (NCT01619358) | National University Hospital, Singapore | 2012-03-01 |
| Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma (NCT01555281) | Swiss Cancer Institute | 2012-02-23 |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma (NCT01547806) | National Cancer Institute (NCI) | 2012-02-22 |
| Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma (NCT01522872) | Threshold Pharmaceuticals | 2012-02-01 |
| Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma (NCT01541332) | Oncotherapeutics | 2012-02-01 |
| Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization (NCT01449539) | University of Arkansas | 2012-02-01 |
| Velcade (Bortezomib) Consolidation After Transplant (NCT01539083) | Janssen Scientific Affairs, LLC | 2012-01-13 |
| Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function (NCT01393964) | Bristol-Myers Squibb | 2012-01-06 |
| Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (NCT01349569) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-01-01 |
| Finistere Myeloma Observatory (OMYFIN) (NCT06552221) | University Hospital, Brest | 2012-01-01 |
| A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors (NCT01457417) | Leap Therapeutics, Inc. | 2012-01-01 |
| Common Safety Follow-up Trial of Tecemotide (L-BLP25) (NCT01423760) | Merck KGaA, Darmstadt, Germany | 2012-01-01 |
| Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency (NCT01337752) | Novartis Pharmaceuticals | 2012-01-01 |
| Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma (NCT01549431) | Emory University | 2012-01-01 |
| A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT01485835) | Emory University | 2012-01-01 |
| Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy (NCT01501370) | Tiziana Marangon | 2012-01-01 |
| Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (NCT01508416) | Centre Hospitalier Universitaire de Saint Etienne | 2012-01-01 |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (NCT01329289) | University of Pittsburgh | 2011-12-01 |
| Phase I Study of CS-7017 and Bexarotene (NCT01504490) | Georgetown University | 2011-12-01 |
| Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens (NCT01502085) | Hackensack Meridian Health | 2011-12-01 |
| Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (NCT01496118) | SCRI Development Innovations, LLC | 2011-12-01 |
| Reduced Intensity Double Umbilical Cord Blood Transplantation (NCT01408563) | Massachusetts General Hospital | 2011-12-01 |
| Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (NCT01428492) | Novartis | 2011-12-01 |
| Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (NCT01478048) | Bristol-Myers Squibb | 2011-11-30 |
| Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (NCT01460420) | European Myeloma Network B.V. | 2011-11-01 |
| ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma (NCT01481194) | Vejle Hospital | 2011-11-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| Music Therapy on Nausea and Pain for Autologous Stem Cell (NCT01487031) | Case Comprehensive Cancer Center | 2011-11-01 |
| Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma (NCT01572688) | Shandong Lanjin Pharmaceuticals Co.,Ltd | 2011-11-01 |
| Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy (NCT01452334) | Bristol-Myers Squibb | 2011-11-01 |
| Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma (NCT01383928) | Millennium Pharmaceuticals, Inc. | 2011-10-31 |
| Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance (NCT01463670) | Memorial Sloan Kettering Cancer Center | 2011-10-28 |
| Providing Access to Cord Blood Units for Transplants (NCT01479582) | National Cancer Institute (NCI) | 2011-10-27 |
| Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies (NCT01416428) | Amgen | 2011-10-15 |
| Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma (NCT01440556) | Azienda Ospedaliera San Giovanni Battista | 2011-10-01 |
| Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma (NCT01438177) | NYU Langone Health | 2011-10-01 |
| Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma (NCT01177735) | University of Arkansas | 2011-10-01 |
| Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma (NCT01495351) | AHS Cancer Control Alberta | 2011-10-01 |
| A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma (NCT01464112) | Janssen Research & Development, LLC | 2011-09-16 |
| Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (NCT01421524) | Celgene | 2011-09-12 |
| Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma (NCT01315873) | NYU Langone Health | 2011-09-01 |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) (NCT01435720) | Senesco Technologies, Inc. | 2011-09-01 |
| MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (NCT01380145) | Ludwig Institute for Cancer Research | 2011-09-01 |
| Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01359657) | Bristol-Myers Squibb | 2011-09-01 |
| A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma (NCT01432353) | Genentech, Inc. | 2011-09-01 |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (NCT01335399) | Bristol-Myers Squibb | 2011-08-04 |
| Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (NCT01348919) | Teva Branded Pharmaceutical Products R&D, Inc. | 2011-08-03 |
| Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) (NCT01352338) | UMC Utrecht | 2011-08-01 |
| Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma (NCT01410981) | Medical University of South Carolina | 2011-08-01 |
| Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma (NCT01421927) | University Hospital, Bordeaux | 2011-08-01 |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (NCT01342289) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-08-01 |
| Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors (NCT01929720) | Ohio State University Comprehensive Cancer Center | 2011-08-01 |
| Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant (NCT01416246) | Memorial Sloan Kettering Cancer Center | 2011-08-01 |
| Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01355705) | Michaela Liedtke | 2011-08-01 |
| Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients (NCT01402284) | National Cancer Institute (NCI) | 2011-07-21 |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT01266811) | Centocor, Inc. | 2011-07-01 |
| Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma (NCT01323751) | Celgene | 2011-07-01 |
| Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (NCT01346787) | European Myeloma Network B.V. | 2011-07-01 |
| Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma (NCT01376401) | PETHEMA Foundation | 2011-07-01 |
| Preservation of Ovarian Function After Hematopoietic Cell Transplant (NCT01343368) | Masonic Cancer Center, University of Minnesota | 2011-07-01 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma (NCT01421186) | MorphoSys AG | 2011-07-01 |
| Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (NCT01454297) | Multiple Myeloma Research Foundation | 2011-07-01 |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT01055301) | SWOG Cancer Research Network | 2011-07-01 |
| Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma (NCT01335685) | Millennium Pharmaceuticals, Inc. | 2011-06-27 |
| Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (NCT01239797) | Bristol-Myers Squibb | 2011-06-20 |
| Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma (NCT01319422) | Yale University | 2011-06-01 |
| Redirected Auto T Cells for Advanced Myeloma (NCT01352286) | GlaxoSmithKline | 2011-05-13 |
| Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma (NCT01351623) | Memorial Sloan Kettering Cancer Center | 2011-05-09 |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma (NCT01484626) | Loyola University | 2011-05-05 |
| Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments (NCT01365559) | Oncotherapeutics | 2011-05-02 |
| An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide. (NCT02528838) | Celgene | 2011-05-01 |
| 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma (NCT01541644) | University of Maryland, Baltimore | 2011-05-01 |
| Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma (NCT02474563) | Janssen Korea, Ltd., Korea | 2011-05-01 |
| Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma (NCT01410929) | DFINE Inc. | 2011-05-01 |
| C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT (NCT01691300) | Chang Gung Memorial Hospital | 2011-05-01 |
| A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (NCT01470131) | AB Science | 2011-05-01 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (NCT01344876) | Otsuka Pharmaceutical Co., Ltd. | 2011-04-01 |
| Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (NCT01339572) | University of Florida | 2011-04-01 |
| Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors (NCT01158118) | Washington University School of Medicine | 2011-04-01 |
| A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (NCT01297764) | Hackensack Meridian Health | 2011-04-01 |
| A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma (NCT01371227) | Janssen Pharmaceutical K.K. | 2011-04-01 |
| Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (NCT01408225) | Ohio State University Comprehensive Cancer Center | 2011-03-17 |
| A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NCT01311687) | Celgene | 2011-03-11 |
| A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea (NCT02556905) | Celgene | 2011-03-09 |
| Retrospective Survey of Re-treatment With Bortezomib (NCT01524445) | Janssen Pharmaceutica N.V., Belgium | 2011-03-01 |
| A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients (NCT01314625) | University of Arkansas | 2011-03-01 |
| Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor (NCT01362972) | Genzyme, a Sanofi Company | 2011-03-01 |
| Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma (NCT01450215) | Karolinska University Hospital | 2011-03-01 |
| Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT (NCT01286675) | Dana-Farber Cancer Institute | 2011-03-01 |
| Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (NCT01283776) | University of Cologne | 2011-03-01 |
| Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma (NCT01324947) | Celgene | 2011-03-01 |
| A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use (NCT02922543) | Celgene | 2011-02-18 |
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma (NCT01145989) | NCIC Clinical Trials Group | 2011-02-15 |
| Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) (NCT01303965) | Sherif S. Farag | 2011-02-07 |
| Clinical Evaluation of the Serum Free Light Chain Analysis (NCT01423344) | Charlotte Toftmann Hansen | 2011-02-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure (NCT01292486) | Terumo BCT | 2011-02-01 |
| Imaging Young Myeloma (IMAgerie JEune Myélome) (NCT01309334) | Nantes University Hospital | 2011-02-01 |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (NCT01237249) | PETHEMA Foundation | 2011-02-01 |